UK vs Germany: How Cannabis Regulations Compare

The German Cannabis Liberalisation of 2024

• Germany legalised recreational cannabis for personal use in April 2024 under the Cannabis Act (CanG), allowing adults to possess up to 25g in public and 50g at home
• Germany also permits non-commercial Cannabis Social Clubs to cultivate and distribute cannabis to members, a unique model in European regulation
• Medical cannabis has been available in Germany since 2017, with GKV (statutory health insurance) covering prescribed cannabis for patients with serious conditions
• German medical cannabis prescribing grew to over 420,000 patients by 2023, significantly ahead of the UK on a per-capita basis

Germany’s regulatory evolution has been rapid and transformative, moving from a conservative medical-only model to Europe’s largest regulated cannabis market, while the UK has maintained a cautious specialist-only prescribing system.

The UK Regulatory Framework

• Cannabis remains a Class B drug in the UK under the Misuse of Drugs Act 1971, with rescheduling in 2018 permitting specialist prescription of Schedule 2 cannabis medicines
• NHS prescribing of cannabis is limited by NICE guidance, with only Epidyolex and Sativex fully endorsed for specific indications
• Private prescribing by licensed specialist clinicians is the primary access route, creating a two-tier system based on ability to pay
• There is no current government policy to follow Germany’s path to broader access; the Advisory Council on the Misuse of Drugs has repeatedly recommended against recreational legalisation

The UK regulatory gap with Germany is widening; while Germany has moved toward broad access including recreational use, the UK maintains a conservative specialist prescribing model with limited NHS coverage.

Quality Standards: Where UK and Germany Align

• Both the UK and Germany require medical cannabis products to meet EU-GMP or equivalent pharmaceutical manufacturing standards
• Batch testing, certificates of analysis, and pharmacovigilance reporting are required in both jurisdictions for medical cannabis medicines
• EU-GMP certification is the common quality language between the two markets, enabling companies such as Cannamedical to supply both legally compliant markets
• The high quality standards in both markets stand in contrast to the unregulated illicit supply that many patients were previously relying upon

On quality standards for medical cannabis, the UK and Germany are well-aligned, both requiring EU-GMP certified products — a shared benchmark that benefits patients and enables international supply chains.

What UK Patients Can Learn from the German Experience

• German GKV reimbursement demonstrated that when cannabis is affordable and accessible, patient populations expand dramatically and health outcomes improve at scale
• The German model shows that broad prescribing can be managed without the public health harms that opponents of liberalisation predicted
• UK patients would benefit from advocating for NHS coverage of medical cannabis, as the German experience shows that costs per patient can be managed at scale
• International travel between the UK and Germany with prescribed cannabis requires documentation from both the British Home Office and the German Federal Opium Agency (BfArM)

The German experience provides a compelling data point for UK policymakers considering how to expand medical cannabis access, demonstrating that broader access is compatible with quality standards and manageable health system costs.